Welcome to our dedicated page for Dassault Systemes news (Ticker: DASTY), a resource for investors and traders seeking the latest updates and insights on Dassault Systemes stock.
DASSAULT SYSTEMES SA ADR (DASTY) news on Stock Titan reflects the official communications of Dassault Systèmes, a software publisher in the information sector whose underlying shares trade on Euronext Paris as DSY.PA. The company’s releases provide insight into its 3DEXPERIENCE platform, virtual worlds strategy and AI-embedded software offerings, as well as its capital markets activity.
Investors following DASTY can use this page to review earnings and financial updates, where Dassault Systèmes reports quarterly and year-to-date revenue, software revenue, recurring revenue, operating margin and diluted earnings per share under IFRS and non-IFRS measures. These announcements also break down software revenue by geography, product line and industry, and highlight the contribution of areas such as Industrial Innovation, Life Sciences and Mainstream Innovation.
The news feed also includes corporate and strategic announcements, such as information about Medidata, a Dassault Systèmes brand that provides clinical trial solutions. Releases describe Medidata Patient, Data and Study Experiences and collaborations with life sciences companies like Sanofi, emphasizing goals such as streamlining clinical workflows, enhancing data quality and accelerating the development of new therapies.
In addition, Dassault Systèmes publishes regulatory and capital markets disclosures, including declarations of the number of outstanding shares and voting rights, reports on trading in its own shares under repurchase programs, and half-year statements on its liquidity contract. Bookmark this page to access a consolidated view of these official updates related to DASTY and the underlying Dassault Systèmes shares.
The "Inspection Management Software Global Market Report 2022" has been added to ResearchAndMarkets.com, highlighting significant growth in the sector. The market is projected to rise from $5.56 billion in 2021 to $6.23 billion in 2022, with an expected CAGR of 12.00%. By 2026, it could reach $9.72 billion at a CAGR of 11.74%. The report covers trends, strategies, and regional analyses, emphasizing the need for digital solutions in maintaining quality standards across various industries, including healthcare and manufacturing. Major players include Dassault Systemes and SAP, underscoring the competitive landscape.
Summary not available.
Data Bridge Market Research has published a report on the E-Clinical Solutions Market, projecting growth from USD 7.2 billion in 2021 to USD 20.54 billion by 2029, at a CAGR of 14.0% during 2022-2029. The report analyzes key growth strategies, market drivers, and competitive landscapes, emphasizing the rising demand for electronic health records and clinical data management systems. Government support for clinical research in emerging economies such as India and China is highlighted as a significant opportunity for market expansion.
3DR Holdings has announced the sixth annual Additive Manufacturing Strategies (AMS) conference, taking place in New York City from February 7-9, 2023. This event aims to explore the future of the additive manufacturing industry amidst challenges such as recessionary trends, global conflicts, and sustainability pushes. The conference will feature over 100 speakers and 30 exhibitors, including notable organizations like Boeing, HP, and NASA. CEO Benny Buller of Velo3D will deliver the opening keynote. The event promises to be a key gathering for 3D printing stakeholders.
On January 10, 2023, Dassault Systèmes announced the half-year update of its liquidity contract with Oddo BHF SCA, revealing resources as of December 31, 2022. The contract included 712,286 shares and €7,510,217.05 in cash. Initially, on contract implementation in 2015, there were 0 shares and €10,000,000 in cash. Subsequent amendments increased the liquidity to €20,000,000. From July 1 to December 31, 2022, the company executed 15,843 purchases and 17,087 sales, totaling 2,738,027 shares traded.
Dassault Systèmes has implemented its governance structure announced on April 27, 2022. Charles Edelstenne transitions to Honorary Chairman, while Bernard Charlès ascends to Chairman and CEO. Pascal Daloz is appointed Deputy CEO, reinforcing a strong leadership team. The governance aims to align with the long-term strategy and enhance the company's growth trajectory. Charlotte Daures serves as Lead Independent Director, focused on Board operations and conflict management. This new leadership structure is expected to drive innovation and sustainable solutions across various industries, enhancing stakeholder value.
Dassault Systèmes announced key metrics as of December 31, 2022. The company reported a total of 1,335,039,708 outstanding shares and 2,001,073,718 voting rights. This calculation includes voting rights tied to all outstanding shares, even those suspended. Shareholders must declare any crossing of thresholds as per General Regulation guidelines. The press release invites shareholders to refer to specific articles for further details and outlines the process for declarations regarding threshold crossings.
Summary not available.
Dassault Systèmes announced the number of outstanding shares and voting rights as of November 30, 2022. The total outstanding shares amounted to 1,334,891,109, while the total voting rights reached 2,033,581,125. These figures are calculated in accordance with the regulations set by the Autorité des marchés financiers. Shareholders are advised to refer to Article 223-11 regarding the declaration of threshold crossings. For further inquiries, contact the Investor Relations team.
OpenFold, a non-profit AI research consortium, has announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. This consortium focuses on developing free and open-source software tools for biology and drug discovery. The growth in membership reflects the momentum from previous developments, including the release of a protein structure prediction AI model. OpenFold aims to leverage AI to enhance drug discovery and accelerate research, benefiting academics and biotech firms alike.